Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIC: Vepoloxamer in Sickle Cell Disease VOC
NCT01737814Phase 3Completed
- Sponsor
- Mast Therapeutics, Inc.
- Start
- May 2013
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of vepoloxamer in sickle cell disease (SCD), sponsored by Mast Therapeutics, Inc.. Started May 2013; status: completed.
02
Drugs
vepoloxamer
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT01737814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01737814.